search
Documents
Released N-Glycan Analysis of Infliximab-dyyb including Sialylated Glycans using a Biozen 2.6 μm Glycan Column
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a Biozen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
Released N-Glycan Analysis of Infliximab-dyyb including Sialylated Glycans using a Biozen 2.6 μm Glycan Column
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a Biozen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
Document Type:
Technical Notes
Target Industries:
Techniques:
Brands:
Separation Modes:
HILIC
Phases:
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide